Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexion Pharmaceuticals, Inc.
Alexion’s Soliris eculizumab Receives Marketing Approval in Australia for All Patients with PNH
March 13th, 2009
Alexion Pharmaceuticals, Inc., (Nasdaq:ALXN) announced that the Australian Government’s Therapeutic Goods Administration has approved the use of Soliris® (eculizumab) for the treatment of all patients in Australia with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Australia for the treatment of PNH. “Prior to this positive action by the government, there has not been an approved, safe and effective therapy for the treatment of patients with PNH in Australia,” said Professor Jeffrey Szer, M.B., B.S., FRACP, Director...
Source: Health Business Week (2009-03-13)
|
